Tag Archive for: antibody-drug conjugates (ADCs)

Mersana Therapeutics Inc. said on Thursday it had signed a deal for developing cancer drugs with Germany’s Merck KGaA that has the potential to generate up to $800 million in milestone payments.

Merck’s bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report published Friday, citing sources familiar with the matter.